Biologics: Market Opportunities for Chemical Suppliers
|出版商||Kline & Company, Inc.||商品編碼||766997|
|生物製劑：化學藥品供應商的市場機會 Biologics: Market Opportunities for Chemical Suppliers|
|出版日期: 2019年08月31日||內容資訊: 英文||
The pharmaceutical industry is witnessing a surge of biologics globally. With higher safety and efficacy, biologic drugs have been found to treat major chronic and complex diseases. In recent years, biologic drugs have enjoyed better approval rate than traditional drugs. However, the development and formulation of biologics bring greater challenges, such as higher R&D investment, longer approval times, a more stringent manufacturing process, and difficult regulatory pathways. With the drug pipeline being increasingly populated with biologics, it is crucial to understand the evolving role of excipients. The selection and use of the right excipients are even more critical for biologics than for small molecule drugs, because excipients are not only key components of the finished biologic drug dosage but also play an important role in the development and manufacturing of the biologic drug itself. Kline aims to provide a comprehensive assessment of excipients in biologics through its new study.
‘Biologics: Market Opportunities for Chemicals Suppliers’ comes as a comprehensive report analyzing market opportunities created by the rapid emergence of biopharmaceutical products throughout their entire value chain, from bioprocessing to formulation (Table 1 & 2) In this study, biologics is referring to recombinant therapeutics, plasma proteins, and vaccines.
This report will assist chemical suppliers in understanding the entire biologics value chain and identifying business opportunities within this key growth area. It will also serve as an invaluable tool in the strategic planning process. This program provides subscribers with a report allowing them to:
Regional Coverage: Global.
* Subject to charter subscriber input.